984 related articles for article (PubMed ID: 18626004)
1. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
17. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
18. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
19. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
20. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
